ifosfamide has been researched along with Carcinoma, Bronchial in 26 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 7.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 3.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| "The early stages of bronchial carcinoma are still a domain of operative treatment." | 2.68 | [Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study]. ( Klinke, F; Micke, O; Rübe, C; von Eiff, M; Wagner, W; Willich, N, 1995) |
| " As compared with the values obtained on day 1, on day 5 the terminal half-life and AUC values determined for IF were reduced by 30% (6." | 1.29 | Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. ( Kurowski, V; Wagner, T, 1993) |
| " Both schedules resulted in a reduction in the elimination half-life with an increased total and nonrenal clearance of ifosfamide over the 5-day period." | 1.28 | Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. ( Cerny, T; Lind, MJ; Margison, JM; Thatcher, N; Wilkinson, PM, 1989) |
| "The most frequent histology was squamous cell carcinoma found in 20 patients." | 1.27 | [Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma]. ( Gatzemeier, U; Hossfeld, DK; Radenbach, D; Zschaber, R, 1985) |
| " There was a proportionate increase in the AUC for the 5-g oral dose, indicating 100% bioavailability at all three dose levels." | 1.27 | Bioavailability of ifosfamide in patients with bronchial carcinoma. ( Cerny, T; Margison, JM; Thatcher, N; Wilkinson, PM, 1986) |
| "Oral ifosfamide therapy was determined to be feasible, and further studies are justified to assess the pharmacokinetics of the optimum dosage and scheduling regimens." | 1.26 | The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma. ( McNiel, NO; Morgan, LR, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (80.77) | 18.7374 |
| 1990's | 4 (15.38) | 18.2507 |
| 2000's | 1 (3.85) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boutemy, M | 1 |
| Mispelaere, D | 1 |
| Krzisch, C | 1 |
| Jounieaux, V | 1 |
| Liesenfeld, A | 1 |
| Havemann, K | 2 |
| Gropp, C | 1 |
| Seifert, W | 1 |
| Thomas, C | 1 |
| Drings, P | 2 |
| Mahnke, HG | 1 |
| Westerhausen, M | 1 |
| Wellens, W | 1 |
| Konrad, RM | 1 |
| Bryant, BM | 1 |
| Jarman, M | 1 |
| Ford, HT | 1 |
| Smith, IE | 1 |
| Valdivieso, M | 4 |
| Cabanillas, F | 1 |
| Keating, M | 1 |
| Barkley, HT | 3 |
| Murphy, WK | 4 |
| Burgess, MA | 1 |
| Frazier, H | 1 |
| Chen, T | 1 |
| Bodey, GP | 3 |
| Seeber, S | 1 |
| Dimitriadis, K | 1 |
| Schütte, J | 1 |
| Schmidt, CG | 1 |
| Matthiessen, W | 2 |
| Stempinski, E | 2 |
| Göbel, D | 2 |
| Thalmann, U | 2 |
| Benjamin, RS | 2 |
| Freeman, MB | 1 |
| Ertel, M | 1 |
| Smith, TL | 1 |
| Mountain, CF | 1 |
| Morgan, LR | 2 |
| Holdiness, MR | 1 |
| Gillen, LE | 1 |
| McNiel, NO | 1 |
| Wagner, W | 1 |
| von Eiff, M | 1 |
| Klinke, F | 1 |
| Micke, O | 1 |
| Rübe, C | 1 |
| Willich, N | 1 |
| Kurowski, V | 2 |
| Wagner, T | 2 |
| Cohen, MH | 1 |
| Ihde, DC | 1 |
| Bunn, PA | 1 |
| Fossieck, BE | 1 |
| Matthews, MJ | 1 |
| Shackney, SE | 1 |
| Johnston-Early, A | 1 |
| Makuch, R | 1 |
| Minna, JD | 1 |
| Holoye, PY | 1 |
| Glisson, BS | 1 |
| Lee, JS | 1 |
| Dhingra, HM | 2 |
| Umsawasdi, T | 2 |
| Levy, JK | 1 |
| Jeffries, D | 1 |
| Raber, MN | 1 |
| Hong, WK | 1 |
| Lind, MJ | 1 |
| Margison, JM | 2 |
| Cerny, T | 2 |
| Thatcher, N | 2 |
| Wilkinson, PM | 2 |
| Banks, J | 1 |
| Anderson, EG | 1 |
| Smith, AP | 1 |
| Manke, HG | 1 |
| Gatzemeier, U | 1 |
| Hossfeld, DK | 1 |
| Radenbach, D | 1 |
| Zschaber, R | 1 |
| Loehrer, PJ | 1 |
| Birch, R | 1 |
| Kramer, BS | 1 |
| Greco, FA | 1 |
| Einhorn, LH | 1 |
| Frankmann, C | 1 |
| McMurtrey, MJ | 1 |
| Jeffries, DG | 1 |
| Welch, SR | 1 |
| Li, GC | 1 |
| Brock, N | 1 |
| Li, JQ | 1 |
| Guan, ZZ | 1 |
| He, YJ | 1 |
| Spitzer, G | 1 |
| Farha, P | 1 |
| Dicke, K | 1 |
| Zander, A | 1 |
| Vellekoop, L | 1 |
| Chiuten, D | 1 |
| Hoefer, H | 1 |
| Scheef, W | 1 |
| Titscher, R | 1 |
| Kokron, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients[NCT01749072] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for ifosfamide and Carcinoma, Bronchial
| Article | Year |
|---|---|
Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
Topics: Acrolein; Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Female; Hematuria; Hu | 1980 |
Role of intravenous hyperalimentation as an adjunct to intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bon | 1981 |
[Neoadjuvant radiochemotherapy in locally advanced non-small cell bronchial carcinoma. Initial results of a prospective multicenter study].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain; Carboplatin; Carcinoma, Bronc | 1995 |
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Bronchoge | 1997 |
Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin | 1979 |
Ifosfamide plus N-acetylcysteine in the treatment of small cell and non-small cell carcinoma of the lung: a Southeastern Cancer Study Group Trial.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic | 1986 |
High-dose intensification therapy with autologous bone marrow support for limited small-cell bronchogenic carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carcinoma, | 1986 |
[Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Topics: Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans | 1974 |
18 other studies available for ifosfamide and Carcinoma, Bronchial
| Article | Year |
|---|---|
[Evaluation of combined chemotherapy with vinorelbine, ifosfamide and cisplatin in the treatment of metastatic non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin | 2005 |
[3 multicenter phase II studies of the treatment of small cell bronchogenic carcinoma (incl. AIO studies BI + BII)].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Ca | 1984 |
Combination chemotherapy of small-cell bronchogenic carcinoma with etoposide (VP-16), ifosfamide and vindesine (VPIV), and with adriamycin, cis-platinum and vincristine (APO).
Topics: Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Cisplatin; Doxorubicin; Drug | 1982 |
Effects of intensive induction chemotherapy for extensive-disease small cell bronchogenic carcinoma in protected environment-prophylactic antibiotic units.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Carcinoma, Bronch | 1984 |
Experimental basis and clinical experience with non-cross-resistant combinations in solid tumours.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bro | 1984 |
Combination chemotherapy with adriamycin, ifosfamide and mesna in extensive-stage non-small cell bronchogenic carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Cyclophosphamide; Doxorubic | 1983 |
N-acetylcysteine: its bioavailability and interaction with ifosfamide metabolites.
Topics: Acetates; Acetylcysteine; Biological Availability; Carcinoma, Bronchogenic; Chemical Phenomena; Chem | 1983 |
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos | 1983 |
The bioavailability of oral and intravenous ifosfamide in the treatment of bronchogenic carcinoma.
Topics: Administration, Oral; Adult; Biological Availability; Carcinoma, Bronchogenic; Cyclophosphamide; Fem | 1981 |
Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy.
Topics: Acetaldehyde; Adult; Aged; Carcinoma, Bronchogenic; Chromatography, Gas; Chromatography, High Pressu | 1993 |
Ifosfamide with mesna uroprotection in the management of lung cancer.
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans | 1990 |
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma.
Topics: Administration, Oral; Adult; Aged; Alkylation; Carcinoma, Bronchogenic; Humans; Ifosfamide; Injectio | 1989 |
Failure of response to ifosfamide in squamous cell bronchogenic carcinoma.
Topics: Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Drug Resistance; Humans; Ifosfamide; Lung Neoplas | 1989 |
[Treatment of non-small-cell bronchial carcinoma with cisplatin, ifosfamide, vindesine and VP 16].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic | 1985 |
[Chemotherapy with mitomycin C, vindesine and ifosfamide in the treatment of inoperable non-small cell bronchial carcinoma].
Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Drug | 1985 |
Long-term effects of intravenous hyperalimentation administered during intensive chemotherapy for small cell bronchogenic carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carcino | 1987 |
Ifosfamide and Mesna in advanced malignancies.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Lymphom | 1988 |
Bioavailability of ifosfamide in patients with bronchial carcinoma.
Topics: Administration, Oral; Aged; Biological Availability; Carcinoma, Bronchogenic; Female; Humans; Ifosfa | 1986 |